Publications by authors named "Krystyna Chimiak"
Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients.
Radiother Oncol
June 2023
Article Synopsis
- This study investigates the survival benefits of combining external beam radiotherapy (EBRT) with brachytherapy boost (BTB) for patients with intermediate- to high-risk prostate cancer, aiming to provide real-world data on survival outcomes.
- Data was gathered from 1,641 patients treated between 2003 and 2014, analyzing overall survival, freedom from distant metastases, and metastases-free survival using statistical models.
- Results showed that patients receiving BTB had significantly better overall survival and reduced rates of metastases compared to those treated with EBRT alone, indicating BTB's effectiveness in improving treatment outcomes for prostate cancer.
The prognostic value of inflammatory indices, such as the absolute monocyte count (AMC), has been a subject of interest in recent prostate cancer (PCa) studies, while hemoglobin concentration (HGB) has been recognized as a survival factor in castration-resistant metastatic prostate cancer, but its value remains unclear in localized diseases. The aim of this study was to test the prognostic value of these two simple and inexpensive biomarkers for survival and was based on a cohort of 1016 patients treated with primary radiotherapy and androgen deprivation therapy for localized or locally advanced intermediate- or high-risk PCa. Complete survival data were available for all cases and were based on the National Cancer Registry, with a median observation time of 120 months (Interquartile Range (IQR) 80.
View Article and Find Full Text PDFPurpose: Serum prostate-specific antigen (PSA) kinetics has been linked to prognosis in prostate cancer (PCa) patients. Our goal was to analyze the association between PSA kinetics and metastasis-free survival (MFS) in patients with localized PCa treated with high-dose-rate (HDR) brachytherapy (BT) boost combined with external beam radiotherapy (EBRT).
Material And Methods: We retrospectively analyzed multiple PSA kinetics related to PSA nadir (nPSA), PSA bouncing, and biochemical recurrence (BCR) in 186 PCa patients treated with neoadjuvant androgen deprivation therapy (ADT), followed by EBRT combined with HDR-BT boost.